Katharina Winkelbach

Title: Katharina Winkelbach: Innovator in Antibody Drug Conjugates

Introduction

Katharina Winkelbach is a prominent inventor based in Basel, Switzerland. She has made significant contributions to the field of biotechnology, particularly in the development of antibody drug conjugates. Her work focuses on innovative solutions for treating cancer, showcasing her dedication to advancing medical science.

Latest Patents

Katharina Winkelbach holds 1 patent for her invention titled "Anti-CD48 antibodies, antibody drug conjugates, and uses thereof." This patent discloses antibodies and antigen binding fragments that specifically bind to human CD48. Additionally, it includes pharmaceutical compositions comprising these antibodies and methods for using them to treat cancer in patients who require treatment.

Career Highlights

Winkelbach is associated with Novartis AG, a leading global healthcare company. Her role at Novartis has allowed her to work on groundbreaking research and development projects that aim to improve patient outcomes through innovative therapies.

Collaborations

Throughout her career, Katharina has collaborated with notable colleagues, including Joseph Anthony D'Alessio and Claudia Judith Klinter. These partnerships have fostered a collaborative environment that enhances the potential for scientific breakthroughs.

Conclusion

Katharina Winkelbach's contributions to the field of biotechnology, particularly in antibody drug conjugates, highlight her role as an influential inventor. Her work continues to pave the way for advancements in cancer treatment, demonstrating the impact of innovation in healthcare.